Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294082 | 0.81 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2KDM4EHSD17B10TSHR | |
| SCHEMBL3397754 | 0.81 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2KDM4EHSD17B10TSHR | |
| SCHEMBL2294079 | 0.81 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2KDM4EHSD17B10TSHR | |
| SCHEMBL13681671 | 0.80 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4ETSHRMAPT | |
| SCHEMBL13270337 | 0.79 | MME (0.51) | ALDH1A1MMEKMT2AMEN1 | |
| SCHEMBL31445041 | 0.79 | ALDH1A1 (0.38) | ALDH1A1HSD17B10MMEACEKMT2A | |
| SCHEMBL9911442 | 0.78 | — | — | |
| SCHEMBL13382227 | 0.77 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2KDM4EHSD17B10TSHR | |
| SCHEMBL13236352 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4EHSD17B10TSHR | |
| SCHEMBL9911432 | 0.76 | ITGB3 (0.38) | ALDH1A1SMN1; SMN2KDM4ETSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | ALDH1A1 411/4885SMN1; SMN2 1896/4885KDM4E 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.